Show simple item record

dc.creatorRao, Vishal
dc.creatorThakur, Shalini
dc.creatorRao, Jyothsna
dc.creatorArakeri, Gururaj
dc.creatorBrennan, Peter A.
dc.creatorJadhav, Sachin
dc.creatorSayeed, Mufti Suhail
dc.creatorRao, Gururaj
dc.date.accessioned2020-07-15T01:40:56Z
dc.date.available2020-07-15T01:40:56Z
dc.date.created2020-10
dc.identifier.issn0306-9877spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0306987720309221?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10534
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectInmunidad innataspa
dc.subjectImunidad adaptativaspa
dc.titleMesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordMesenchymal stem cells-bridgespa
dc.identifier.doihttps://doi.org/10.1016/j.mehy.2020.109845spa
dc.description.abstractenglishMajority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14–20 days. However, about 15% of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (<65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system.spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record